For the Inventor, By the Inventor

Enter assignee name

Allschwil, Switzerland

Actelion Pharmaceuticals Ltd

USPTO Granted Patents = 217

% Expired Patents = 62.7

CIPO Patents = 69

EPO Patents = 143

Trademarks = 24

Forward Citations = 1,075

Loading Chart...

Loading Chart...

195 inventors (with patents filed for the assignee):

Martin Bolli (50 out of 66 patents)

Christoph Boss (43 out of 59 patents)

Oliver Nayler (37 out of 38 patents)

4. Boris Mathys (32 out of 34 patents)

5. Claus Mueller (32 out of 36 patents)

6. Hamed Aissaoui (31 out of 38 patents)

7. Christian N Hubschwerlen (29 out of 61 patents)

8. Martine Clozel (27 out of 44 patents)

9. Thierry Sifferlen (27 out of 40 patents)

10. Thomas Weller (24 out of 54 patents)

11. Kurt Hilpert (22 out of 44 patents)

12. Georg Rueedi (21 out of 25 patents)

13. Jean-Philippe Surivet (21 out of 27 patents)

14. Sylvia Richard-Bildstein (20 out of 29 patents)

15. Markus Gude (20 out of 27 patents)

Core Competencies:

Pulmonary Arterial Hypertension

Selexipag

Macitentan

S1P1 Receptor Agonists

NADPH Oxidase 4 Inhibitors

Pyrimidine Derivatives

ALX Receptor Agonists

Orexin Receptor Antagonists

Tricyclic Compounds

Antibacterial Derivatives

Therapeutic Compositions

Dosing Regimens

217 patents: Sort by Forward Citations

1. 12485119 - Methods of treating pulmonary arterial hypertension (2025-12-02),

2. 12419887 - Transitioning patients treated for pulmonary arterial hypertension to selexipag (2025-09-23),

3. 12121516 - Pharmaceutical composition comprising selexipag (2024-10-22),

4. 11771683 - Dosing regimen for a selective S1Preceptor agonist (2023-10-03),

5. 11723896 - Pharmaceutical combination comprising ponesimod (2023-08-15),

6. 11672783 - Pharmaceutical combination comprising a selective S1P1 receptor agonist (2023-06-13),

7. 11648249 - Stable pharmaceutical compositions comprising a pyrimidine-sulfamide (2023-05-16),

8. 11612600 - Pharmaceutical composition comprising macitentan for the treatment of chronic thromboembolic pulmonary hypertension (2023-03-28),

9. D974921 - Pharmaceutical package (2023-01-10),

10. 11464777 - Pharmaceutical composition for the treatment of pulmonary arterial hypertension (2022-10-11),

11. 11234980 - Pharmaceutical composition for the treatment of pulmonary arterial hypertension (2022-02-01),

12. 11136317 - NADPH oxidase 4 inhibitors (2021-10-05),

13. 11026927 - Pharmaceutical combination comprising a selective S1P1 receptor agonist (2021-06-08),

14. 10946015 - Stable pharmaceutical compositions comprising a pyrimidine-sulfamide (2021-03-16),

15. 10857134 - Dosing regimen for a selective S1Preceptor agonist (2020-12-08),

Actelion Pharmaceuticals Ltd, headquartered in Allschwil, Switzerland, specializes in the development and commercialization of innovative therapies for pulmonary hypertension. The company is recognized for its pioneering work in treating pulmonary arterial hypertension, with key products including Selexipag and Macitentan. Actelion's research focuses on advanced therapeutic areas such as S1P1 receptor agonists and NADPH oxidase 4 inhibitors, contributing significantly to the understanding and management of complex cardiovascular conditions.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Actelion Pharmaceuticals Ltd

217 Patents

#1 in Allschwil

#82 in Switzerland

#3,936 in the World

Allschwil, Switzerland

Actelion Pharmaceuticals Ltd

Forward Citations = 1,075

195 inventors:

Martin Bolli (50 out of 66 patents)

Christoph Boss (43 out of 59 patents)

Oliver Nayler (37 out of 38 patents)

4. Boris Mathys (32 out of 34 patents)

5. Claus Mueller (32 out of 36 patents)

Please report any incorrect information to [email protected]

Loading…